Comparison of crossover and parallel‐group designs for the identification of a binary predictive biomarker of the treatment effect
Open Access
- 16 July 2019
- journal article
- research article
- Published by Wiley in Basic & Clinical Pharmacology & Toxicology
- Vol. 126 (1) , 59-64
Abstract
Pros and cons of crossover design are well known for estimating the treatment effect compared to parallel‐group design, but remain unclear for identifying and estimating an interaction between a potential biomarker and the treatment effect. Such ‘predictive’ biomarkers, or ‘effect modifiers’, help to predict the response to specific treatments. The purpose of this report was to better characterize the advantages and disadvantages of crossover versus parallel‐group design to identify predictive biomarkers. The treatment effect, the effect of a binary biomarker and their interaction were modelled using a linear model. The intra‐subject correlation in the crossover design was taken into account through an intra‐class correlation coefficient. The variance‐covariance matrix of the parameters was derived and compared. For both trial designs, the variance of the parameter estimating an interaction between the treatment effect and a potential predictive biomarker corresponds to the variance of the parameter estimating the treatment effect, multiplied by the inverse of the frequency of the candidate biomarker. The ratio of the variance of the interaction parameter in the crossover to the variance estimated in the parallel‐group design depends on the complement of the intra‐class correlation coefficient. When planning a clinical trial including a search for candidate biomarker, the frequency of the candidate biomarker helps design the sample size, and the intra‐subject correlation of the outcome should be taken into account for choosing between parallel‐group and crossover designs.Keywords
This publication has 15 references indexed in Scilit:
- An in silico approach helped to identify the best experimental design, population, and outcome for future randomized clinical trialsJournal of Clinical Epidemiology, 2016
- Designing a study to evaluate the benefit of a biomarker for selecting patient treatmentStatistics in Medicine, 2015
- A recommended analysis for 2 × 2 crossover trials with baseline measurementsPharmaceutical Statistics, 2014
- Impact of misspecifying the distribution of a prognostic factor on power and sample size for testing treatment interactions in clinical trialsBMC Medical Research Methodology, 2013
- Parallel, AA/BB, AB/BA and Balaam's design: efficient and maximin choices when testing the treatment effect in a mixed effects linear regressionPharmaceutical Statistics, 2012
- A statistician's perspective on biomarkers in drug developmentPharmaceutical Statistics, 2011
- Integrating biomarkers in clinical trialsExpert Review of Molecular Diagnostics, 2011
- Efficiency of the cross‐over design: an empirical estimationStatistics in Medicine, 2004
- Subgroup analyses in randomized trials: risks of subgroup-specific analyses;Journal of Clinical Epidemiology, 2004
- The analysis of data from 2 × 2 cross‐over trials with baseline measurementsStatistics in Medicine, 1987